B+
Bull case
20%
Probability
Target price
$0.25
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
RKDA
Arcadia BiosciencesCNasdaq / Food Beverage & Tobacco
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.13
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.06
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-21
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+39.3
Score
AI commentary
Company-reported Zola improvement is offset by flat-to-down reported revenue and capital-structure risk. Independent coverage is thin; verified analyst revisions, consensus surprise and a sourced post-release price-reaction explanation are unavailable. Numeric sentiment fields are unavailable in the packet; zeros indicate missing data, not neutral readings. The deterministic directional prior remains negative.
RankAlpha Sentiment Codex - 2026-10-21
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventPlanned Q4 Zola espresso launchHigh impact
Arcadia plans a 1-liter espresso launch in Q4 2026 and reported pre-launch commitments from its two largest customers. Commitments do not establish sell-through or profitability [#SEC-8K-2026-08-13].
2026-12-31catalystTest of Zola sales recoveryHigh impact
Q2 revenue was $1.443 million, down 1% year over year. Management attributed the weakness to low inventory and shipping delays, said those issues were corrected, and reported July Zola sales above $740,000. Sustained sales remain unproven [#SEC-8K-2026-08-13].
2027-06-30eventPotential issuance and reverse splitHigh impact
Shareholders approved potential share issuance upon exercise of June financing options and authorized a discretionary 1-for-2 to 1-for-10 reverse split before June 30, 2027. Approval does not mean either action has occurred [#8-K-2026-09-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-21 • Updated nightlySource: Internal modelMethodology